Roche has gained US regulatory approval for satralizumab (Enspryng), an IL-6 receptor monoclonal antibody (mAb), in adults with thyroid eye disease (TED), making it the first TED therapy that patients can self-administer by subcutaneous injection at home.

The approval rests on SatraGO-1 and SatraGO-2, which enrolled 258 adults with active moderate-to-severe or inactive TED and measured proptosis response, defined as at least 2 mm improvement from baseline at week 24; in SatraGO-2, proptosis response was 52.9% for satralizumab versus 23.4% for placebo (p=0.0011), and clinical activity score improvements were consistently superior, while SatraGO-1 showed a numerical but not statistically significant proptosis advantage, 49.0% versus 31.2%, alongside significant CAS benefits.

Satralizumab binds soluble and membrane-bound IL-6R in a pH-dependent manner and was first approved in 2020 for AQP4-positive neuromyelitis optica spectrum disorder, so the TED label extends Roche's IL-6 franchise into a high-unmet-need ocular autoimmune market. Among the four globally approved TED therapies, veligrotug, teprotumumab and IBI311 are intravenous, giving Roche a delivery-mode edge in convenience, adherence and infusion-capacity constraints.